Biotechnology
Serentrix is focused on developing novel therapies for pain to address opioid epidemic. Our Phase 2 ready compound is a novel molecule which has prior human exposure with a strong safety profile and proven MOAs relevant for neuropathic and IBS pain. Additional opportunity exists for the asset in Dry Eye, AMD, Uveal melanoma and Women's health.